Almirall has taken another step forwards in the development of a digital approach to managing and treating dermatological conditions, forming a three-year alliance with Mi
The European Commission has approved Almirall’s lebrikizumab as Ebglyss for the treatment of moderate-to-severe atopic dermatitis (AD), with an EU rollout set to start in
A few months after raising €200 million in investment capital to boost its pipeline, Spanish drugmaker Almirall has used some of the cash for a bispecific antibody partner
Almirall is within sniffing distance of EU approval for its IL-13 inhibitor lebrikizumab for atopic dermatitis, setting up a challenge to Sanofi and Regeneron’s market-lea
Spanish pharma Almirall has closed a €200 million share capital raise that will be used in part to close pipeline-boosting activities – including bolt-on acquisitions and
With the northern hemisphere summer drawing near, a campaign has been launched to raise awareness of actinic keratosis – a skin condition caused by sun exposure that can l
Endeavor BioMedicines has completed a third-round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.